Literature DB >> 8855292

An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.

J S Anderson1, M Teutsch, Z Dong, H H Wortis.   

Abstract

Mutations of the Bruton's tyrosine kinase (btk) gene cause X-linked agammaglobulinemia (XLA) in humans and X-linked immune deficiency (Xid) in mice. To establish the BTK role in B-cell activation we examined the responses of wild-type and Xid B cells to stimulation through surface IgM and CD40, the transducers of thymus independent-type 2 and thymus-dependent activation, respectively. Wild-type BTK was necessary for proliferation induced by soluble anti-IgM (a prototype for thymus independent-type 2 antigen), but not for responses to soluble CD40 ligand (CD40L, the B-cell activating ligand expressed on T-helper cells). In the absence of wild-type BTK, B cells underwent apoptotic death after stimulation with anti-IgM. In the presence of wild-type but not mutated BTK, anti-IgM stimulation reduced apoptotic cell death. In contrast, CD40L increased viability of both wild-type and Xid B cells. Importantly, viability after stimulation correlated with the induced expression of bcl-XL. In fresh ex vivo small resting B cells from wild-type mice there was only barely detectable bcl-XL protein, but there was more in the larger, low-density ("activated") splenic B cells and peritoneal B cells. In vitro Bcl-XL induction following ligation of sIgM-required BTK, was cyclosporin A (CsA)-sensitive and dependent on extracellular Ca2+. CD40-mediated induction of bcl-x required neither wild-type BTK nor extracellular Ca2+ and was insensitive to CsA. These results indicate that BTK lies upstream of bcl-XL in the sIgM but not the CD40 activation pathway. bcl-XL is the first induced protein to be placed downstream of BTK.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855292      PMCID: PMC38267          DOI: 10.1073/pnas.93.20.10966

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Regulation of B cell survival in xid mice by the proto-oncogene bcl-2.

Authors:  R T Woodland; M R Schmidt; S J Korsmeyer; K A Gravel
Journal:  J Immunol       Date:  1996-03-15       Impact factor: 5.422

2.  LPS-activated CBA/N mouse B cells respond to anti-Ig and a BSF-1-like factor.

Authors:  M Howard; P Pesavento; P Stein
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

3.  Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia.

Authors:  D Campana; J Farrant; N Inamdar; A D Webster; G Janossy
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

4.  New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures.

Authors:  R Y Tsien
Journal:  Biochemistry       Date:  1980-05-27       Impact factor: 3.162

5.  Activation and proliferation signals in mouse B cells. I. A comparison of the capacity of anti-Ig antibodies or phorbol myristic acetate to activate B cells from CBA/N or normal mice into G1.

Authors:  C M Hawrylowicz; K D Keeler; G G Klaus
Journal:  Eur J Immunol       Date:  1984-03       Impact factor: 5.532

6.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes.

Authors:  C L Sentman; J R Shutter; D Hockenbery; O Kanagawa; S J Korsmeyer
Journal:  Cell       Date:  1991-11-29       Impact factor: 41.582

7.  Role of the thymus in directing the development of a subset of B lymphocytes.

Authors:  J J Mond; I Scher; J Cossman; S Kessler; P K Mongini; C Hansen; F D Finkelman; W E Paul
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

8.  Activation of murine B lymphocytes by anti-immunoglobulin is an inductive signal leading to immunoglobulin secretion.

Authors:  D C Parker; D C Wadsworth; G B Schneider
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

9.  Frequency of B lymphocytes responsive to anti-immunoglobulin.

Authors:  A L Defranco; E S Raveche; R Asofsky; W E Paul
Journal:  J Exp Med       Date:  1982-05-01       Impact factor: 14.307

10.  Lack of mature B cells in nude mice with X-linked immune deficiency.

Authors:  H H Wortis; L Burkly; D Hughes; S Roschelle; G Waneck
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2.

Authors:  Iris Castro; Jacqueline A Wright; Bazarragchaa Damdinsuren; Kristen L Hoek; Gianluca Carlesso; Nicholas P Shinners; Rachel M Gerstein; Robert T Woodland; Ranjan Sen; Wasif N Khan
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

3.  Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes.

Authors:  David A Fruman; Gregory Z Ferl; Sam S An; Amber C Donahue; Anne B Satterthwaite; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

4.  Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase.

Authors:  G M Dingjan; A Maas; M C Nawijn; L Smit; J S Voerman; F Grosveld; R W Hendriks
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

Review 5.  X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.

Authors:  C I Smith; C M Bäckesjö; A Berglöf; L J Brandén; T Islam; P T Mattsson; A J Mohamed; S Müller; B Nore; M Vihinen
Journal:  Springer Semin Immunopathol       Date:  1998

6.  The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation.

Authors:  G Texido; I H Su; I Mecklenbräuker; K Saijo; S N Malek; S Desiderio; K Rajewsky; A Tarakhovsky
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

7.  Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.

Authors:  Samantha M Jaglowski; Jeffrey A Jones; Veena Nagar; Joseph M Flynn; Leslie A Andritsos; Kami J Maddocks; Jennifer A Woyach; Kristie A Blum; Michael R Grever; Kelly Smucker; Amy S Ruppert; Nyla A Heerema; Gerard Lozanski; Mona Stefanos; Brian Munneke; Jamie-Sue West; Jutta K Neuenburg; Danelle F James; Nathan Hall; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-06-26       Impact factor: 22.113

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

10.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.